Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is a clinical-stage biopharmaceutical company with a diversified pipeline and promising clinical candidate, zanidatamab, targeting HER2-expressing tumors. With a discounted cash flow analysis, a target firm value of ~$3.8B was calculated, and the management has a positive outlook on zanidatamab's approval in multiple indications. Risks to the positive outlook include clinical trial failures, competition, regulatory risks, and sector risks. However, with a strong partnership with Jazz Pharma and a promising pipeline, Zymeworks' stock has a potential upside in the future.

Bears say

Zymeworks is a biopharmaceutical company that has a negative outlook, mainly due to limited direct insight into Johnson & Johnson's decision to expand Phase 3 enrollment for Zymeworks' pasritamig, and the company's dependence on clinical trials for its valuation. Additionally, Zymeworks faces marketing, biotech sector, clinical trial, and stock price volatility risks. Financially, the company may struggle to create incremental shareholder value in the near term due to limited pipeline options. Based on a DCF through 2034, Zymeworks has a target price of $17, assuming a 9% WACC and 0.5% terminal growth rate.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.